Navigated Robot System
2. Cutting System
-- D -- H -- M
Since Launch
MEET MONOGRAM
The future of orthopedic medicine is personal.
MONOGRAM ORTHOPAEDICS, INC. IS TESTING THE WATERS UNDER TIER 2 OF REGULATION A. NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC.
YOU MAY OBTAIN A COPY OF THE PRELIMINARY OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM https://www.sec.gov/Archives/edgar/data/1769759/000110465920139028/tm2029060d8_partiiandiii.htm
Up to 10% Bonus depending on investment!
Investors that invest at least $5,000 in this offering will receive a 5% bonus and investors that invest at least $10,000 will receive a 10% bonus on their investment.
Indicate your interest:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Example: if an investor reserves 100 shares, and subsequently confirms this reservation and purchases the 100 shares, such investor will receive an additional 10 shares of the company’s Series B Preferred Stock, for a total of 110 shares. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.
Company Highlights
We believe we are on track to be the first company to market with an active milling navigated robot arm with 3D printed patient-optimized implants. Now is the time for us to ramp the intensity and push even harder towards our mission.
Expect revenue in 2021
2 active distributors and expect sales of licensed implants
World-class team
Led by top surgeons and experts in robotics and medical technology
350 sq. ft. cadaver lab complete
Development and demo lab with dedicated robotics in 4,000 sq. ft. Austin facility
8 Patent Applications Filed
We believe we will be early to market with our novel technology and a Freedom to Operate on our knee implant
Have already raised $16.7M
We have been developing our technology since 2016 and now have the support of 6,793 investors
Over 1 million knee replacements
Up to 10% of total knee replacements fail on an annual basis.
Solving Real Problems
it is estimated that up to one third of TKA recipients experience chronic pain postoperatively.
Joint replacement technology has, in many ways, remained the same for 40 to 50 years. Often crude and finicky instruments like saws and jigs are used to prepare the bone for geometric and rigid generic implants that don't accurately fit. Insertions are often eyeballed and subject to proper surgeon execution. We have designed the Monogram workflow for efficiency and unwavering accuracy.
50% of early revision total knee arthroplasties related to instability, malalignment or malposition, and failure of fixation.
Knees
Rate of re-admission:
7%-8%.
Approximately 50%-75% are surgical.
36%
Survey: 36% of TKA patients would not have undergone the surgery knowing what it did for them (10 years later).
1 in 5
1 in 5 patients are not satisfied with the results of their total knee replacement.
Potentially Preventable Reasons for revision Procedure
19%
10%
7%
5%
Up to 10% Bonus depending on investment!
Investors that invest at least $5,000 in this offering will receive a 5% bonus over $5,000 on their investment. Investors that invest at least $10,000 will receive a 10% bonus over $10,000. Investors receiving the 5% bonus will pay an effective price of approximately $5.95 per share before the StartEngine processing fee, while investors receiving the 10% bonus will pay an effective price of approximately $5.64 per share before the StartEngine processing fee.
Indicate your interest:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Example: if an investor reserves 100 shares, and subsequently confirms this reservation and purchases the 100 shares, such investor will receive an additional 10 shares of the company’s Series B Preferred Stock, for a total of 110 shares. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.
Building Critical Infrastructure to Scale Growth
Executed agreements with 2 distributors and expect to sign more distributors in key markets.
We have licensed certain FDA approved, clinically well established implant components that will be integrated into our proprietary Monogram knee system. Monogram will leverage the testing and proven performance of these components (articulation, locking mechanisms, inserts) to focus on our novel tibial component and robotics.
Implants designed for uncemented stability.
Monogram implants rely on natural biologic fixation and are smaller, bone conserving, and more stable.
Implant
Monogram Results
Orthopedic implants are generic and indistinguishable. The industry is using the same implant and instrument ideology that it has been for the past 50 years. It's time to use technology to change the game.
Patient-optimized bone sparing press-fit implants
The leading generic equivalent had up to 270% more micromotion than Monogram
The cementless total knee market is expected to grow by $1.2BN from 2020 to 2024 (22% CAGR)
Approximately 95% of hip implants are press-fit
Will uncemented knee adoption follow the hip trend?
In a period of 10 years, the use of cement decreased from 54% to 4% in 2019. Similarly, we anticipate there could be a significant decrease in the use of cement in knee replacements over the next decade or so.
Tibia
Closed Loop Tracking
For safety Monogram has implemented a "closed-loop" system. The real-time position of the cutting system is tracked at all times.
Increased Range of Motion
Seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage the kinematic redundancy to avoid interoperative boundaries and optimize execution.
Active Navigated Milling
High-efficiency rotary cutting system to gently excavate the negative space for the patient-optimized implant.
Robotic Surgical Assistants
Monogram’s navigated surgical robot features several enhancements that will improve surgical experiences including:
Disrupting the Joint Replacement Market
$19.6B
Joint Replacement Market
Less than 65 yrs fastest growing demographic
Patients less than 65 years of age represent the fastest-growing population of TKR recipients, expected to account for more than 50% of knee replacement procedures by the year 2030
82% combined share
Four companies currently dominate the multi-billion dollar joint reconstruction market with an 82% combined share in knees
3.5 million
Annual Total Knee Replacement procedures by the year 2030
Over 1 million
Knee replacements in US annually
Stryker (Mako) is the only navigated robot arm on the market with a cutting end-effector. Monogram believes we will be the first active navigated arm on the market.
By 2027, approximately 50% of all knee procedures will be robotic, up from 11% in 2019
Significant Increases
in robotic adoption are expected over the next 5-10 years.
At least 50% of procedures will be robotic by 2027
Estimates for procedure volumes vary but TKA projections are generally between 935,000 and 1,260 and 1,260,000 by 2030
Monogram implants will not use cement! They will be cementless or press-fit.
Porous Coated for bone ingrowth ("Osseointegration")
No Cement Used
The Technology Platform
Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms.
The Robotics
Monogram’s navigated robot features several enhancements that will improve user experience compared to robots currently in use. Specifically, the Monogram robot will feature tracking cameras mounted directly on the robot to mitigate line-of-sight issues. The robot will feature seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage kinematic redundancy to avoid inoperative boundaries and optimize surgical execution. The robot will also utilize complex tracking capabilities for soft-tissue avoidance.
Our Implants
Monogram implants are designed such that cortical contact and stability are maximized while remaining insertable and designed to reconstruct the native patient anatomy as closely as possible. Monogram will commercialize the first patient specific hip and knee to address the primary clinical shortcomings of their generic counterparts.
The Technology Platform
Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms.
The Robotics
Monogram’s navigated robot features several enhancements that will improve user experience compared to robots currently in use. Specifically, the Monogram robot will feature tracking cameras mounted directly on the robot to mitigate line-of-sight issues. The robot will feature seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage kinematic redundancy to avoid inoperative boundaries and optimize surgical execution. The robot will also utilize complex tracking capabilities for soft-tissue avoidance.
Our Implants
Monogram implants are designed such that cortical contact and stability are maximized while remaining insertable and designed to reconstruct the native patient anatomy as closely as possible. Monogram will commercialize the first patient specific hip and knee to address the primary clinical shortcomings of their generic counterparts.
The Plan
Monogram is building the future of orthopedics one step at a time
2017 Seed Round #1
$1,032,000 convertible note round.
Oct 12, 2017
First patent application published
UCLA Hip Studies
Q1 2018
Nebraska Knee Studies
2018 Seed Round #2
$1,148,000 convertible note round.
Q1 2019
3D Printing Mechanical Testing
Q1 2020
Strategic Engineering Hires
TKA Licensing Agreement
April 2020
$14,568,568 Series-A round
Q3 2020
Surgeon Advisory Board
Signed First Monogram Distributor
Q4 2020
First Monogram Cadaver Lab
15 Full-time Employees
August 2021
Exhibit Product System to American
Academy of Orthopaedic Surgeons (AAOS)
Academy of Orthopaedic Surgeons (AAOS)
2021
Revenues
$30,000,000 capacity Series-B Close
Monogram Implant Submission
Monogram 2nd Gen Implants
- Insertion with manual instruments & robotics
- 510(k) Submission
- Expecting to finalize design in 2020 - cadaver lab
- Expecting to demo at AAOS in August 2021
2023
Monogram Robot Submission
Monogram Surgical Robot
- Designed for Gen 2 implant
- 510(k) Submission
- Expect to conduct robotic cadaveric testing in 2021
3. Implants
4. Navigation Consumables
5. Cutting Tools
6. Software
Navigated Robot System
2. Cutting System
3. Implants
4. Navigation Consumables
5. Cutting Tools
6. Software
The Business Model
We believe that precision implants with precision insertion are the future of orthopaedics. Monograms principal competitive advantage will be our ability to produce customized, robotically inserted orthopaedic implants rapidly and at scale. The product solution architecture we are developing enables rapid fabrication and mass personalization of robotically inserted, patient specific orthopaedic implants.
Our Facilities
Our cadaver lab features a simulated surgical theatre with cadaveric storage and sterile reprocessing capabilities with a dedicated robotic surgical system that will be used exclusively for development engineering and surgical demonstrations. We expect the lab will not only drive commercialization efficiencies, but we will conduct regular demonstrations with surgeons, distributors, and key opinion leaders to cultivate market interest in the product pipeline.
Austin Texas
Based
4,000 sq. ft.
Headquarters
With 350 sq. ft
Cadaver lab
.jpg)
Meet the Team
See Our Team
Douglas Unis, Md
Founder & Chief Medical Officer
Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.
Benjamin Sexson - CEO
CFA, Chief Executive Officer
Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.
Paul Riss
CPA, MBA, INTERIM CFO
Experienced executive with a demonstrated history of completing SEC filings, focusing on the Securities Exchange Act of 1934 and Section 4(a)(6) of the Securities Act of 1933. Currently serves as a Director for NetCapital and was a CPA with Ernst & Young.
Sherif Aly, P.hD.
VP Engineering
Sherif was instrumental to the development of the Mako Orthopedic Robot and Implant systems. After the Mako acquisition, he was the Sr Director of Robotics Development Program Management, reporting to the VP of Robotics R&D, and was responsible for managing all Stryker Joint Replacement robotics development programs (over 250 engineers at 7 sites worldwide). Most recently, Sherif was the VP of Engineering and Regulatory Affairs at Xenex Disinfection Systems.
Christopher Scifert, P.hD.
Director of Product Development Implants and Instruments
Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.
Richard Jackson
Director of Software
Before joining Monogram, Richard was a Software and Systems Engineering Manager at Biolase Inc., based in Irvine, CA. Richard has over 20 years of software engineering experience, including experience in regulated industries, and has held various management roles.
Mark Cole
Director of Quality and Regulatory Assurance
Before joining Monogram, Mark was the Director, Quality and Product Development at Vigilant Biosciences Inc. Mark has over 20 years of experience, including experience in various Quality and Regulatory management roles.
Sophia Sangiorgio, PhD
Director, Orthopaedic Institute for Children
Laura Gilmour
Global Medical B. Development Manager at EOS NA
Matt DiCicco, M.S.
Robotics, MIT
Dr. Roshan Shah
Director of Complex Adult Hip and Knee Reconstruction at Columbia University
Robert Jamieson
Board Certified Orthopaedic Surgeon at The Orthopedic Specialty Center of Northern California
Dr. Matthew E. Heinrich
Total Joint Replacement Specialist at Orthopaedic Specialists of Austin
Darwin Chen
Associate Professor of Orthopaedics at Icahn School of Medicine at Mt Sinai
Dr. Gregory Catlett
Total Joint Replacement Specialist at Orthopaedic Specialists of Austin
Up to 10% Bonus depending on investment!
Investors that invest at least $5,000 in this offering will receive a 5% bonus over $5,000 on their investment. Investors that invest at least $10,000 will receive a 10% bonus over $10,000. Investors receiving the 5% bonus will pay an effective price of approximately $5.95 per share before the StartEngine processing fee, while investors receiving the 10% bonus will pay an effective price of approximately $5.64 per share before the StartEngine processing fee.
Indicate your interest:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Example: if an investor reserves 100 shares, and subsequently confirms this reservation and purchases the 100 shares, such investor will receive an additional 10 shares of the company’s Series B Preferred Stock, for a total of 110 shares. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.